Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
May 1999

TacrolimusThe Drug for the Turn of the Millennium?

Author Affiliations

From the Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany.


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Dermatol. 1999;135(5):574-580. doi:10.1001/archderm.135.5.574

Background  Tacrolimus has been shown to be a powerful suppressor of the immune system. It was introduced into clinical use to prevent allograft rejection and is now routinely used in kidney, liver, and heart transplantation. Recently, 2 double-blind multicenter studies demonstrated the therapeutic efficacy of topical and systemic tacrolimus in the inflammatory skin diseases atopic dermatitis and psoriasis.

Data Source  MEDLINE was searched for relevant publications and combined with our own clinical, in vitro, and in vivo studies.

Study Selection  All studies dealing with tacrolimus and dermatology were reviewed.

Data Extraction  Publications with clinically relevant data were included in this review.

Conclusions  Topical tacrolimus is a safe and effective therapeutic agent that may open a new era in the treatment of inflammatory skin diseases, particularly for patients with atopic dermatitis. Before its full potential in dermatology can be assessed, more clinical experience in treating children and comparison with the criterion standard of anti-inflammatory therapy, glucocorticosteroids, are needed.